85 results about "Allergic inflammation" patented technology

This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.

Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.

This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.

The invention provides methods and compositions for treating allergic inflammation by combining cytokine antagonists capable of acting synergistically to reduce allergic inflammation in a subject. Methods of in vivo screening for therapeutically effective cytokine antagonists useful for treating allergic inflammation are also provided.

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and / or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

The present invention relates to methods for delivery of fusion polypeptides into cells. Methods are provided for local delivery of fusion polypeptides, e.g., through the skin, eye and the airway, to prevent allergic inflammation, airway hyper-responsiveness and to block T cell activation. Methods for delivery of fusion polypeptides to suppress graft rejection are also provided.

CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression.

Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and / or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

A method and system for exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments.

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and / or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.

This invention relates to a system for and method for medical treatment of respiratory diseases. The system and method are particularly effective for the treatment of and protection from diseases associated with allergic inflammation. Suitable diseases for treatment include atopic asthma, rhinitis, sinusitis, and conjunctivitis.

The present invention discloses a pharmaceutical preparation of Chinese herbal medicines which consists of Chinese herbal medicines for tonifying kidney and antiasthma, wherein the Chinese herbal medicines are Perilla Frutescens, Prunus Armeniaca, Glycyrrhiza Uralensis, Scutellaria Baicalensis, Coptis Chinesis, Tusilago Farfara, Stemona Sessilifolia, Fritllaria Cirrhosa, Pheretima Aspergillum, Psoralea Corylifolia, Codonopsis Pilosula, Hordeum Vulgara, Massa Fermentata Medicalis, Schisandra Chinensis, Gypsum. The preparation has been used in China for 20 years, and in Israel for more than 5 years. It has been used to treat thousands of patients suffering from asthma with an effective rate of 93%. The present preparation can relieve cough, expel phlegm, resist airway allergic inflammation reaction, improve pulmonary function, partial pressure of the oxygen in blood and increase CD2, CD4, CD4 / CD8, reduce IgE in blood, and increase CAMP, reduce CGMP, stabilize mast cells, inhibit the release of histamine, which makes it capable of stopping the attack of asthma. As shown with an electron microscope, the preparation protects lung cells, increases lung cells of type 2, and recovers the lung's capacity. It can be applied to the hormone dependent patients for decreasing and ceasing the administration of hormone by adjusting hypothalamic-pituitary-adrenal axis. To further demonstrate the therapeutic effect, a clinical trial carried in the Tel-Hashomer Hospital of Israel proved the preparation can improve asthma significantly.

This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.

Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions.

The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

This invention relates to a system for and method for medical treatment of respiratory diseases. The system and method are particularly effective for the treatment of and protection from diseases associated with allergic inflammation, or infectious diseases. Suitable allergic diseases for treatment include atopic asthma, rhinitis, sinusitis, and conjunctivitis.

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and / or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are tetrahydroquinoline derivatives.

The invention relates to a composition for preventing or treating allergic diseases by using black rice extract and the therapeutic application of the composition. More specifically, the present invention relates to a composition for preventing or treating allergic diseases, which composition contains the following substances as active ingredients: pelargonidin, cyanidin glycoside or containing pelargonidin and Black rice extract of anthocyanins; the invention also relates to the therapeutic use of said composition. Anthocyanin, anthocyanin or black rice extract containing anthocyanin and anthocyanin inhibit the aggregation of eosinophils in the tissue, and thus have an inhibitory effect on allergic inflammation, so the above substances can be effectively For the prevention or treatment of allergic diseases associated with inflammation and eosinophil accumulation, such as allergic rhinitis, allergic conjunctivitis, asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic Sexual diarrhea etc.

Disclosed are methods for treating or preventing allergic inflammation in a subject and methods for treating or preventing one or more symptoms of allergic inflammation in a subject. The methods include administering to the subject a compound which inhibits reactive oxygen species. Also disclosed are methods for reducing a non-animal-derived allergen's ability to initiate an allergenic process and for reducing prooxidant activity of a non-animal-derived allergen. The methods include contacting the non-animal-derived allergen with an agent which inhibits reactive oxygen species. Methods for screening a compound for its usefulness as an agent for reducing a non-animal-derived allergen's ability to initiate an allergenic process and / or for its usefulness as a therapeutic agent for treating or preventing allergic inflammation and / or the symptoms associated therewith are also disclosed.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and / or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders / other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.

The present invention provides for the use of a calpain inhibitor for the treatment of allergy diseases, inflammatory diseases and autoimmune diseases. In particular, it has been found that inhibition of calpain within mast cells decreases the release of chemical mediators into the surrounding environment, resulting in a decreased local inflammatory response. The present invention also provides for a method of decreasing IgE-dependent mast cell degranulation, mast cell mediator release and cytokine production in mast cells, comprising the step of administering to the mast cells an effective amount of a calpain inhibitor.

Pharmaceutical compositions for treating immunological disorders and the preparing method of the same are disclosed, which include alcohol extracts of Radix Dioscorea, Rhizoma Alismatis, Poria cocos (schw) Wolf, and Scutellaria Baicalensis. The compositions are manufactured by novel procedures consisting of decocting using specific concentration ranges of alcohol, filtering, regulating pH value, purifying, concentrating, proportionally mixing, and making a granule powder from lyophilized extract. This invention used both in vitro and in vivo assays to evaluate therapeutic effects of specific combination of herbal plant extracts. The combination of herbal extracts has been able to maximize the anti-inflammatory activity and regulate the secretion of cytokines such as eotaxin and IL-4. When the pharmaceutical composition of the present invention is used for asthma, it can relieve coughs, resist airway allergic inflammation reactions, improve the pulmonary functions, reduce allergen specific IgE in bloods, stabilize elasmatoblasts, and stop the attacks from asthma.

The invention relates to a desloratadine external preparation and a preparation method thereof. The external preparation takes desloratadine as a main drug and is used for treating allergic skin inflammation. The desloratadine external preparation can increase the concentration of free drug in skin local tissues of the part with the allergic skin inflammation of a body through percutaneous absorption, have an effective histamine sensitization antagonism role, better play local antianaphylaxis and anti-inflammation efficacies and reduce adverse reactions. The external formulation does not pass through the gastrointestinal tract, thereby avoiding the first pass effect and reduce the probability of occurrence of adverse reactions. The external preparation can be directly applied at the affected side, and the onset of action is rapid. Furthermore, the dose and the coverage area of the external preparation can be selected according to the area and the severity of the affected site, and the external preparation is convenient to use and convenient to carry.

A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.

The invention discloses a sunscreen skin care product comprising pigment, antimicrobial peptide, plant extracting solution, a sun-screening agent, grease, an emulsifying agent, a humectant and deionized water, wherein the pigment is selected from one or more from chlorophyll a, chlorophyll b, chlorophyll c, chlorophyll d, carotene and xanthophyll. The chlorophylls are added in the sunscreen skin care product, thereby effectively blocking UVA (Ultraviolet A) and reducing injury of illumination on skin, UVB (Ultraviolet B) incapable of being absorbed by the chlorophylls is absorbed by the sun-screening agent, the chlorophylls are combined with the sun-screening agent to better block the ultraviolet radiated by the sun, thereby improving the sunscreen effect of the sunscreen skin care product. The added antimicrobial peptide and the plant extracting solution can effectively prevent and treat allergic inflammation phenomenon of skin, speed up the recovery of the injured skin and have the functions of maintaining moisture and moistening skin at the same time.

The invention discloses application of gentiopicroside and a gentiopicroside preparation, particularly discloses non-treatment application of the gentiopicroside serving as a calcineurin (CAN)-NF-AT pathway blocker and application of the gentiopicroside to preparation of the calcineurin (CAN)-NF-AT pathway blocker, and further discloses application of the gentiopicroside to preparation of an external preparation or daily chemical product for preventing or treating skin hypersensitivity inflammatory reaction. The gentiopicroside stemming from dried roots and rhizomes of Gentiana lutea is capable of blocking a CAN-NF-AT pathway to effectively prevent or treat skin allergy symptoms such as eczema and contact dermatitis caused by excessive immune response and can be prepared into various daily chemical products or external preparations. A gentiopicroside synthetic process used herein is mature, preparation cost is low, popularization and application are benefited, and accordingly the gentiopicroside is promising in application prospect.

The invention relates to the field of microorganisms, and specifically discloses Lactobacillus paracasei and its application. The preservation number of Lactobacillus paracasei in the present invention is CGMCC No.8903, which is isolated from feces of children and belongs to Lactobacillus paracasei subspecies. The strain of the present invention proliferates rapidly and has excellent acid production ability, has the ability to secrete extracellular polysaccharides and resist the invasion of bile salts and gastric acid, and can regulate immune responses, inhibit allergies and inflammation, and is very suitable for food, health care products, and medicines , food supplements and other products.

The cytokine ML-1 is a target for treating airway inflammation. Candidate therapeutic agents for treating airway inflammation can be screened for the ability to bind to an ML-1 protein or polynucleotide, from the ability to decrease functional properties of ML-1, or for the ability to decrease ML-1 gene expression. Pharmaceutical compositions comprising such reagents can be used to treat airway inflammation associated with a variety of lung disorders, such as asthma, chronic obstructive pulmonary disease, emphysema, allergic inflammatory responses, and cystic fibrosis.

Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.